3-碘-6-甲氧基苯甲酰胺123I在人体中的体内特性研究。
In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans.
作者信息
Costa D C, Verhoeff N P, Cullum I D, Ell P J, Syed G M, Barrett J, Palazidou E, Toone B, Van Royen E, Bobeldijk M
机构信息
Institute of Nuclear Medicine, UCMSM, London, UK.
出版信息
Eur J Nucl Med. 1990;16(11):813-6. doi: 10.1007/BF00833017.
3-Iodo-6-methoxybenzamide (123I-IBZM), a new Dopamine D2 receptor ligand, was used in conjunction with SME 810 brain tomography to study six subjects (one normal volunteer, four schizophrenics and one DAT patient). Initial Dynamic SPET was followed by multislice SPET. High-resolution images of the D2 receptor distribution in the basal ganglia were obtained. The specific binding in D2 receptors of the basal ganglia is highest from 2-4 h p.i. Patients on anti-psychotic drugs showed significantly lower specific binding. Dopamine D2 brain receptor availability in man may now be studied with SPET. Continuous data acquisition with single slice tomography is particularly important in the study of this type of radiotracers.
3-碘-6-甲氧基苯甲酰胺（123I-IBZM），一种新型多巴胺D2受体配体，与SME 810脑断层扫描技术联合使用，对六名受试者（一名正常志愿者、四名精神分裂症患者和一名多巴胺转运体（DAT）患者）进行了研究。首先进行动态单光子发射计算机断层扫描（SPET），随后进行多层SPET扫描。获得了基底神经节中D2受体分布的高分辨率图像。基底神经节D2受体的特异性结合在注射后2至4小时最高。服用抗精神病药物的患者显示出明显较低的特异性结合。现在可以用SPET研究人体中的多巴胺D2脑受体可用性。在这类放射性示踪剂的研究中，采用单层断层扫描进行连续数据采集尤为重要。
Zotero 插件